NeuroLink Brain
NeuroLink Brain Raises $580M Series D to Transform Healthcare
Quick Facts
NeuroLink Brain
Brain-computer interface technology enabling paralyzed patients to control devices with thought and treating depression through targeted neural stimulation.
About the Funding
NeuroLink Brain has successfully raised $580M in a Series D funding round, bringing their total valuation to $8.2B. This significant investment will fuel the company's mission to complete fda approval process, scale manufacturing for clinical deployment, and expand treatment applications.
Use of Funds
Complete FDA approval process, scale manufacturing for clinical deployment, and expand treatment applications
Company Overview
Brain-computer interface technology enabling paralyzed patients to control devices with thought and treating depression through targeted neural stimulation.
Key Investors
- • Google Ventures
- • Johnson & Johnson
- • Medtronic Ventures
- • Peter Thiel
Founders
- • Dr. Neural Science
- • Dr. Brain Tech
Previous Rounds
Market Impact
This funding round positions NeuroLink Brain as a leader in the MedTech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.